BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 3093069)

  • 1. Relationship between circulating plasminogen activators and tumor development in mice.
    Colombi M; Rebessi L; Boiocchi M; Barlati S
    Cancer Res; 1986 Nov; 46(11):5748-53. PubMed ID: 3093069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasminogen activators in nude mice xenotransplanted with human tumorigenic cells.
    Colombi M; Bellotti D; De Petro G; Barlati S
    Invasion Metastasis; 1995; 15(1-2):22-33. PubMed ID: 7672929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice.
    de Vries TJ; Kitson JL; Silvers WK; Mintz B
    Cancer Res; 1995 Oct; 55(20):4681-7. PubMed ID: 7553649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between urokinase-type plasminogen activator production and the metastatic ability of human rectal cancer cells.
    Marutsuka K; Suzumiya J; Kataoka H; Komada N; Koono M; Sumiyoshi A
    Invasion Metastasis; 1991; 11(4):181-91. PubMed ID: 1765431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracellular matrix produced by cultured corneal and aortic endothelial cells contains active tissue-type and urokinase-type plasminogen activators.
    Korner G; Bjornsson TD; Vlodavsky I
    J Cell Physiol; 1993 Mar; 154(3):456-65. PubMed ID: 8436596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urokinase (u-PA) is produced by collecting duct principal cells and is post-transcriptionally regulated by SV40 large-T, arginine vasopressin, and epidermal growth factor.
    Piedagnel R; Tiger Y; Lelongt B; Ronco PM
    J Cell Physiol; 2006 Feb; 206(2):394-401. PubMed ID: 16155905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retinoic acid modulates extracellular urokinase-type plasminogen activator activity in DU-145 human prostatic carcinoma cells.
    Waghray A; Webber MM
    Clin Cancer Res; 1995 Jul; 1(7):747-53. PubMed ID: 9816041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucocorticoid modulation of plasminogen activators and of one of their inhibitors in the human mammary carcinoma cell line MDA-MB-231.
    Busso N; Belin D; Failly-Crépin C; Vassalli JD
    Cancer Res; 1987 Jan; 47(2):364-70. PubMed ID: 3098408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma.
    De Petro G; Tavian D; Copeta A; Portolani N; Giulini SM; Barlati S
    Cancer Res; 1998 May; 58(10):2234-9. PubMed ID: 9605771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of sympathetic activity by tissue plasminogen activator is independent of plasminogen and urokinase.
    Schaefer U; Vorlova S; Machida T; Melchor JP; Strickland S; Levi R
    J Pharmacol Exp Ther; 2007 Jul; 322(1):265-73. PubMed ID: 17429057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human hepatoma cell line plasminogen activator.
    Levin EG; Fair DS; Loskutoff DJ
    J Lab Clin Med; 1983 Oct; 102(4):500-8. PubMed ID: 6311924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastasis of human colon tumor cells in vivo: correlation with the overexpression of plasminogen activators and 72 kDa gelatinase.
    Shah V; Kumar S; Zirvi KA
    In Vivo; 1994; 8(3):321-6. PubMed ID: 7803712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mouse trophoblastic cell lines: II--Relationship between invasive potential and proteases.
    Sharma RK
    In Vivo; 1998; 12(2):209-17. PubMed ID: 9627804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombin enhances release of tissue plasminogen activator from bovine corneal endothelial cells.
    Fukushima M; Nakashima Y; Sueishi K
    Invest Ophthalmol Vis Sci; 1989 Jul; 30(7):1576-83. PubMed ID: 2501229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presence of urokinase in serum-free primary rat hepatocyte cultures and its role in activating hepatocyte growth factor.
    Mars WM; Kim TH; Stolz DB; Liu ML; Michalopoulos GK
    Cancer Res; 1996 Jun; 56(12):2837-43. PubMed ID: 8665523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasminogen-dependent and -independent proteolytic activity of murine endothelioma cells with targeted inactivation of fibrinolytic genes.
    Lijnen HR; Wagner EF; Collen D
    Thromb Haemost; 1997 Feb; 77(2):362-7. PubMed ID: 9157597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro.
    Paciucci R; Torà M; Díaz VM; Real FX
    Oncogene; 1998 Feb; 16(5):625-33. PubMed ID: 9482108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
    Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
    J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human primary colon carcinomas xenografted into nude mice. II. Modulation of tumor plasminogen activator activity by the host tissue environment.
    Cajot JF; Sordat B; Bachmann F
    J Natl Cancer Inst; 1986 Nov; 77(5):1099-107. PubMed ID: 3095580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
    Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
    Thromb Haemost; 1988 Oct; 60(2):247-50. PubMed ID: 3146141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.